Towards Healthcare
mRNA Therapeutics CDMO Market Size Grows to USD 5.15 Billion in 2025

mRNA Therapeutics CDMO Market Growth Driven by AI Integration and Clinical Expansion – 2025 Insights

Based on market forecasts, the mRNA therapeutics CDMO sector will expand from USD 4.62 billion in 2024 to USD 13.63 billion by 2034, experiencing a CAGR of 11.37%.The growing demand for vaccines and the rising prevalence of chronic disorders drive the market. The availability of state-of-the-art research and development facilities and increasing government funding contribute to North America’s dominance.

Content

  • Insight Code: 5831
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The mRNA therapeutics CDMO market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2025 to 2034.

North America is leading the mRNA therapeutics CDMO market due to the availability of state-of-the-art research and development facilities, technological advancements, and increasing government funding.

The mRNA therapeutics CDMO market includes 5 segments including by service type, by application, by scale of operation, by end-user, and by region.

Some key players include Lonza Group AG, Catalent, Inc., Evonik Industries AG, and Integrated DNA Technologies.

Key trends include the rising prevalence of chronic and genetic disorders, the growing need for vaccines, and the increasing collaborations among key players.

The main role of mRNA is to carry protein information from the DNA in a cell’s nucleus to the cell cytoplasm.

mRNA vaccines work by introducing a piece of mRNA that corresponds to a viral protein, enabling cells to produce the viral protein. The immune system recognizes the protein as foreign and generates antibodies to fight against it.

Clinicaltrials.gov, World Health Organization, Press Information Bureau, Government of Canada
Any Questions